Haematological cancer: Idelalisib for CLL - risky benefit.

Haematological cancer: Idelalisib for CLL - risky benefit.

Nat Rev Clin Oncol. 2017 Feb 14;:

Authors: Romero D

PMID: 28195233 [PubMed - as supplied by publisher]

http://ift.tt/2kwQ4wd